Lykke M. Ornbjerg

Glostrup, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study.

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study.

Journal: EULAR rheumatology open

Published: June 29, 2026

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Journal: The Journal of rheumatology

Published: June 15, 2026

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Journal: The Journal of rheumatology

Published: June 15, 2026

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: a European cohort study.

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: a European cohort study.

Journal: Joint bone spine

Published: May 13, 2026

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: A European cohort study.

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: A European cohort study.

Journal: Joint bone spine

Published: May 13, 2026

Defining and validating a high specificity MRI cut-off for the radiographic part of the modified New York criteria in patients with axial spondyloarthritis.

Defining and validating a high specificity MRI cut-off for the radiographic part of the modified New York criteria in patients with axial spondyloarthritis.

Journal: Arthritis research & therapy

Published: January 06, 2026

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Journal: RMD open

Published: October 28, 2025

Discrepancies between routine sacroiliac joint MRI reporting and current expert recommendations in patients with spondyloarthritis.

Discrepancies between routine sacroiliac joint MRI reporting and current expert recommendations in patients with spondyloarthritis.

Journal: RMD open

Published: September 01, 2025

Assessing internal construct validity of DAPSA and DAPSA28 in psoriatic arthritis: a European observational study using confirmatory factor analysis and additional psychometric testing.

Assessing internal construct validity of DAPSA and DAPSA28 in psoriatic arthritis: a European observational study using confirmatory factor analysis and additional psychometric testing.

Journal: RMD open

Published: July 07, 2025

Sacroiliac joint involvement in psoriatic arthritis - MRI, radiographic and clinical findings in 581 European routine care patients.

Sacroiliac joint involvement in psoriatic arthritis - MRI, radiographic and clinical findings in 581 European routine care patients.

Journal: Arthritis research & therapy

Published: June 04, 2025

Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis.

Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis.

Journal: ACR open rheumatology

Published: April 17, 2025

Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm.

Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm.

Journal: Annals of the rheumatic diseases

Published: February 25, 2025

Showing 1-12 of 77

Last Updated: 09/26/2026